update desk

FDA clears new ReWalk product for stroke survivors

Israel-based ReWalk Robotics Ltd. announced that its ReStore product will have a starting price in the United States of $28,900, though leasing options will be available.

ReWalk Robotics Ltd.’s ReStore, an exoskeleton for stroke survivors. Credit: Screenshot.
ReWalk Robotics Ltd.’s ReStore, an exoskeleton for stroke survivors. Credit: Screenshot.

The Food and Drug Administration has cleared a new product geared to help stroke survivors walk again.

Israel-based ReWalk Robotics Ltd. announced on Tuesday that its ReStore product will have a starting price in the United States of $28,900, though leasing options will be available.

Last week, ReStore received the CE mark, allowing it to be sold in the European Union.

ReWalk Robotics Ltd. is known for its exoskeleton that enables paraplegics to walk again. It received FDA clearance in 2014.

You have read 3 articles this month.
Register to receive full access to JNS.

Just before you scroll on...

Israel is at war. JNS is combating the stream of misinformation on Israel with real, honest and factual reporting. In order to deliver this in-depth, unbiased coverage of Israel and the Jewish world, we rely on readers like you. The support you provide allows our journalists to deliver the truth, free from bias and hidden agendas. Can we count on your support? Every contribution, big or small, helps JNS.org remain a trusted source of news you can rely on.

Become a part of our mission by donating today
Topics
Comments
Thank you. You are a loyal JNS Reader.
You have read more than 10 articles this month.
Please register for full access to continue reading and post comments.
Never miss a thing
Get the best stories faster with JNS breaking news updates